Loading...
NASDAQ: CBAY
CymaBay Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$3.73B
52w High
$32.50
52w Low
$7.26
P/E
-32.74
Volume
8.35M
Outstanding Shares
114.79M
Not enough data to analyse price vs. fundamentals for this ticker.
Company profile
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
CEOSujal A. Shah
SectorHealthcare
IndustryBiotechnology
Employees101
IPO dateFeb 3, 2014
Valuation
Forward P/E—
EV/EBITDA-28.18
Enterprise value$2.42B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin97.81%
Operating margin-327.23%
ROE-36.05%▲89.04%vs FY2022
Analyst consensus
RatingHold
Target price—
11
Buy
12
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Feb 28, 2024
View
EPS
Actual vs estimate by quarter
Q3FY23
ActualEst.
-$0.01
-$0.21
Q4FY23
ActualEst.
-$0.32
-$0.30
Q1FY24
ActualEst.
-$0.35
-$0.32
Q2FY24
Next Est.
—
Revenue
Actual vs estimate by quarter
Q3FY23
ActualEst.
$31.02M
$9.9M
Q4FY23
ActualEst.
—
$310K
Q1FY24
ActualEst.
$57K
$40K
Q2FY24
Next Est.
—